Literature DB >> 10590234

O(6)-methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes.

C L Nutt1, N A Loktionova, A E Pegg, A F Chambers, J G Cairncross.   

Abstract

We observed previously that wild-type p53 rendered neonatal mouse astrocytes resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a gene dose-dependent fashion. This effect of p53 appeared to be unrelated to its cell cycle regulation or apoptotic functions. Because in many cell types O(6)-methylguanine-DNA methyltransferase (MGMT)-mediated DNA repair is an important mechanism of resistance to nitrosoureas, we measured MGMT activity in wild-type, heterozygous and p53 knockout neonatal mouse astrocytes. Wild-type p53 astrocytes had significantly greater MGMT activity than either heterozygous or p53 knockout astrocytes: MGMT activity was approximately 5-fold greater in wild-type p53 astrocytes than in p53 knockout cells. However, despite successful depletion of MGMT activity in wild-type astrocytes by O(6)-benzylguanine (BG), resistance to BCNU persisted unchanged. Moreover, we excluded the possibility that continued resistance to BCNU at the concentrations used could be explained by a compensatory induction of MGMT triggered by exposure to either BCNU or BG. Although these studies support a role for p53 regulation of MGMT in neonatal mouse astrocytes, BCNU resistance in wild-type cells appears to be mediated by a non-MGMT mechanism. Nevertheless, regulation of DNA repair by MGMT may be another mechanism by which alterations of the p53 gene promote tumor initiation or progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10590234     DOI: 10.1093/carcin/20.12.2361

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  2 in total

1.  Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.

Authors:  George C Bobustuc; Cheryl H Baker; Arati Limaye; Wayne D Jenkins; Gary Pearl; Nicholas G Avgeropoulos; Santhi D Konduri
Journal:  Neuro Oncol       Date:  2010-06-04       Impact factor: 12.300

2.  Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.

Authors:  J L Blanc; M Wager; J Guilhot; S Kusy; B Bataille; T Chantereau; F Lapierre; C J Larsen; L Karayan-Tapon
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.